Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 9/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9405720 | 1.00 | MAPT (0.37) | MAPTGAAMEN1KMT2AOPRL1 | |
| SCHEMBL7738847 | 1.00 | MAPT (0.37) | MAPTGAAMEN1KMT2AOPRL1 | |
| SCHEMBL9405715 | 1.00 | MAPT (0.37) | MAPTGAAMEN1KMT2AOPRL1 | |
| SCHEMBL7738849 | 1.00 | MAPT (0.37) | MAPTGAAMEN1KMT2AOPRL1 | |
| SCHEMBL9406276 | 0.99 | MAPT (0.39) | MAPTGAAMEN1KMT2AOPRL1 | |
| SCHEMBL9406132 | 0.99 | MAPT (0.39) | MAPTGAAMEN1KMT2AOPRL1 | |
| SCHEMBL9405923 | 0.99 | MAPT (0.39) | MAPTGAAMEN1KMT2AOPRL1 | |
| SCHEMBL9406282 | 0.99 | MAPT (0.39) | MAPTGAAMEN1KMT2AOPRL1 | |
| SCHEMBL9406127 | 0.99 | MAPT (0.39) | MAPTGAAMEN1KMT2AOPRL1 | |
| SCHEMBL9405927 | 0.99 | MAPT (0.39) | MAPTGAAMEN1KMT2AOPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6458433-B1 | ISOTOPE REPLACEMENT; OPTICAL DISPLAY | CHISSO CORPORATION (JP) | 2002-10-01 | — | — | US | disclosed |
| US-20020038858-A1 | Isotope replacement; optical display | JNC CORPORATION (JP) | 2002-04-04 | — | — | US | disclosed |
| EP-0949232-A1 | DIFLUOROPHENYL DERIVATIVES, LIQUID-CRYSTAL COMPOUNDS, AND LIQUID-CRYSTAL COMPOSITION | CHISSO CORPORATION (JP) | 1999-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020038858-A1 | Isotope replacement; optical display | IRS1, FES, IK | MAPT 600/4885GAA 4848/4885MEN1 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.